The top-selling product for French pharmaceutical giant Sanofi now has two more competitors in the U.S. market, as the Food and Drug Administration on Friday approved medicines from AbbVie and Pfizer for the treatment of eczema.
AbbVie's Rinvoq and Pfizer's Cibinqo each work by suppressing Janus kinases, or JAKs, a group of proteins that regulate the immune system and inflammation. Rinvoq had previously been cleared by the FDA to treat two kinds of arthritis, whereas Friday's approval was the first for Cibinqo in the U.S.
Both AbbVie's and Pfizer's drugs are taken orally, a convenience which could eventually help them compete against injectable eczema treatments like Sanofi and Regeneron's Dupixent. Over the first nine months of 2021, Sanofi recorded 3.7 billion euros
